TP53 and B-cell chronic lymphocytic leukemia: This question will probably be answered by the CLL13 trial (NCT02950051), which compares CIT (FCR or BR) vs. various combinations of venetoclax (Ve), rituximab (R), obinutuzumab (G) and ibrutinib (I) (RVe vs. GVe vs. GIVe) in treatment-naïve, fit CLL patients without del(17p) or TP53 mutation [40].